Reports
Sale
Global Biopharmaceuticals Market Size, Growth, Trends: By Product Type: Monoclonal Antibodies, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Vaccines, Recombinant Enzyme, Cell and Gene Therapies, Others; By Therapeutic Application; Regional Analysis; Supplier Landscape; 2024-2032
Global Biopharmaceuticals Market Outlook
The global biopharmaceuticals market size was valued at USD 438.79 billion in 2023, driven by the increasing prevalence of chronic diseases, advancements in the medical sector, and the growing investments by the leading life sciences companies. The market is anticipated to grow at a CAGR of 7.6% during the forecast period 2024-2032 to reach a value of USD 848.34 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Monoclonal Antibodies Segment Predicted to Hold a Significant Market Share over the Forecast Period
Based on product type, monoclonal antibodies (MAbs) are expected to hold a significant share in the biopharmaceuticals industry during the forecast period, owing to their increased therapeutic applications to treat chronic disorders and in the field of oncology. They are developed artificially in laboratories using biotechnological tools. Monoclonal antibodies are used to cure different types of autoimmune conditions, infectious diseases, and cancer. Their lower toxicity and enhanced safety compared to chemotherapy drugs have proven to improve patient survival rates and reduce adverse side effects. These factors are expected to aid the growth of the segment in the coming years.
North America Secured the Largest Market Share and is Anticipated to Retain its Dominance in the Forecast Period
Geographically, North America is anticipated to dominate the global market for biopharmaceuticals during the forecast period. The increasing investments in research and development activities and the growing burden of chronic disease are the key factors driving the biopharmaceuticals industry growth in North America. Meanwhile, the biopharmaceuticals industry is expected to grow at a significant CAGR in the Asia Pacific region during the forecast period due to an increase in the number of people suffering from diabetes and other chronic diseases and the increased availability of biopharmaceutical products in the region.
Biopharmaceuticals: Market Segmentation
Biopharmaceuticals are medicinal products containing proteins, sugars, nucleic acid, tissues, and living cells derived from various biological sources such as animals, microorganisms, and humans. In 1982, recombinant human insulin (Humulin) made from specially modified bacteria was the first biopharmaceutical approved by the food and drug administration (FDA) for human therapeutic uses and marketing. Following the success of Humulin, various types of biopharmaceuticals have been derived from recombinant DNA such as whole blood, vaccine, antigens, hormones, immunosera, enzymes, cytokines, monoclonal antibodies, allergenic, and gene therapies, among others.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By product type, the industry can be segmented into:
- Monoclonal Antibodies
- Anti-Cancer Monoclonal Antibodies
- Anti-Inflammatory Monoclonal Antibodies
- Others
- Recombinant Growth Factors
- Erythropoietin
- Granulocyte Colony Stimulating Factor
- Purified Proteins
- Leukemia Inhibitory Factor (LIF)
- P53 Protein
- P38 Protein
- Others
- Recombinant Proteins
- Serum Albumin
- Amyloid Protein
- Defensin
- Transferrin
- Recombinant Hormones
- Recombinant Human Growth Hormones
- Recombinant Insulin
- Others
- Vaccines
- Recombinant Vaccines
- Cancer Vaccines
- Malaria Vaccines
- Ebola Vaccine
- Hepatitis B Vaccine
- Tetanus Vaccine
- Diphtheria Vaccine
- Cholera Vaccines
- Others
- Conventional Vaccines
- Polio Vaccine
- Pox Vaccine
- Others
- Recombinant Vaccines
- Recombinant Enzymes
- Enterokinase
- Cyclase
- Caspase
- Cathepsin
- Cell and Gene Therapies
- Allogenic Products
- Autologous Products
- Acellular Products
- Synthetic Immunomodulators
- Cytokines, Interferons, and Interleukins
- Others
Based on therapeutic application, the industry can be divided into:
- Oncology
- Inflammatory and Infectious Diseases
- Autoimmune Disorders
- Metabolic Disorders
- Hormonal Disorders
- Cardiovascular Diseases
- Neurological Diseases
- Others
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Increase in Research and Development Activities to Bolster the Growth of the Global Biopharmaceuticals Industry
The biopharmaceuticals industry has been growing considerably for the last few years. The biopharmaceutical products are widely used in the treatment of diabetes, cancer, rheumatoid arthritis, and psoriasis. Extensive use of biopharmaceuticals in the treatment of chronic diseases, such as diabetes, cancer, and heart diseases, is a key factor expected to propel the market growth during the forecast period. Moreover, the growing research and development activities by the major pharmaceutical companies and the rapid advancements in genetic engineering are the key trends in the market, which are expected to further propel the biopharmaceuticals industry.
Key Industry Players in the Global Biopharmaceuticals Market
The report gives a detailed analysis of the following key players in the global biopharmaceuticals market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Amgen Inc.
- AbbVie Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Novo Nordisk A/S
- Pfizer Inc.
- GlaxoSmithKline plc.
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Therapeutic Application |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Biopharmaceuticals Market Overview
3.1 Global Biopharmaceuticals Market Historical Value (2017-2023)
3.2 Global Biopharmaceuticals Market Forecast Value (2024-2032)
4 Global Biopharmaceuticals Market Landscape
4.1 Global Biopharmaceuticals Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Biopharmaceuticals Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Therapeutic Application
5 Global Biopharmaceuticals Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Biopharmaceuticals Market Segmentation
6.1 Global Biopharmaceuticals Market by Product Type
6.1.1 Market Overview
6.1.2 Monoclonal Antibodies
6.1.2.1 Anti-Cancer Monoclonal Antibodies
6.1.2.2 Anti-Inflammatory Monoclonal Antibodies
6.1.2.3 Others
6.1.3 Recombinant Growth Factors
6.1.3.1 Erythropoietin
6.1.3.2 Granulocyte Colony Stimulating Factor
6.1.4 Purified Proteins
6.1.4.1 Leukemia Inhibitory Factor (LIF)
6.1.4.2 P53 Protein
6.1.4.3 P38 Protein
6.1.4.4 Others
6.1.5 Recombinant Proteins
6.1.5.1 Serum Albumin
6.1.5.2 Amyloid Protein
6.1.5.3 Defensin
6.1.5.4 Transferrin
6.1.6 Recombinant Hormones
6.1.6.1 Recombinant Human Growth Hormones
6.1.6.2 Recombinant Insulin
6.1.6.3 Others
6.1.7 Vaccines
6.1.7.1 Recombinant Vaccines
6.1.7.1.1 Cancer Vaccines
6.1.7.1.2 Malaria Vaccines
6.1.7.1.3 Ebola Vaccine
6.1.7.1.4 Hepatitis B Vaccine
6.1.7.1.5 Tetanus Vaccine
6.1.7.1.6 Diphtheria Vaccine
6.1.7.1.7 Cholera Vaccines
6.1.7.1.8 Others
6.1.7.2 Conventional Vaccines
6.1.7.2.1 Polio Vaccine
6.1.7.2.2 Pox Vaccine
6.1.7.2.3 Others
6.1.8 Recombinant Enzyme
6.1.8.1 Enterokinase
6.1.8.2 Cyclase
6.1.8.3 Caspase
6.1.8.4 Cathepsin
6.1.9 Cell and Gene Therapies
6.1.9.1 Allogenic Products
6.1.9.2 Autologous Products
6.1.9.3 Acellular Products
6.1.10 Synthetic Immunomodulators
6.1.10.1 Cytokines, Interferons, and Interleukins
6.1.11 Others
6.2 Global Biopharmaceuticals Market by Therapeutic Application
6.2.1 Market Overview
6.2.2 Oncology
6.2.3 Inflammatory and Infectious Diseases
6.2.4 Autoimmune Disorders
6.2.5 Metabolic Disorders
6.2.6 Hormonal Disorders
6.2.7 Cardiovascular Diseases
6.2.8 Neurological Diseases
6.2.9 Others
6.3 Global Biopharmaceuticals Market by Region
6.3.1 Market Overview
6.3.2 North America
6.3.3 Europe
6.3.4 Asia Pacific
6.3.5 Latin America
6.3.6 Middle East and Africa
7 North America Biopharmaceuticals Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Biopharmaceuticals Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Biopharmaceuticals Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Biopharmaceuticals Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Biopharmaceuticals Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Amgen Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 AbbVie Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Bristol-Myers Squibb Company.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Eli Lilly and Company
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Novo Nordisk A/S
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Pfizer Inc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 GlaxoSmithKline plc.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Abbott
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Astrazeneca
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 F. Hoffmann-La Roche Ltd.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Merck & Co., Inc.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Bayer AG
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Biogen
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
18 Global Biopharmaceuticals Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The global biopharmaceuticals market reached a value of USD 438.79 billion in 2023.
The market is anticipated to grow at a CAGR of 7.6% during the forecast period of 2024-2032 to reach a value of USD 848.34 billion by 2032.
The increasing prevalence of chronic diseases, advancements in the medical sector, and the growing investments by the leading life sciences companies are the major factors propelling the growth of the market.
The key market trends guiding the growth of the industry include the rise in research and development activities by pharmaceutical companies and the advancements in genetic engineering.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share in the market.
Monoclonal antibodies, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, vaccines, recombinant enzymes, cell and gene therapies, and synthetic immunomodulators, among others are the significant product types in the industry.
Oncology, inflammatory and infectious diseases, autoimmune disorders, metabolic disorders, hormonal disorders, cardiovascular diseases, and neurological diseases, among others are the significant therapeutic applications of the product.
The major players in the industry are Amgen Inc., AbbVie Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Novo Nordisk A/S, Pfizer Inc., and GlaxoSmithKline plc., among others.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER